News Multiple Sclerosis Association, Antidote Technologies Collaborate to Raise Clinical-trial Awareness Multiple Sclerosis Association, Antidote Technologies Collaborate to Raise Clinical-trial Awareness by Patricia Silva, PhD | January 16, 2017 Share this article: Share article via email Copy article link The Multiple Sclerosis Association of America (MSAA) and Antidote TechnologiesĀ announced a partnership to increase awareness aboutĀ clinical trials on multiple sclerosis (MS) and to make important information more accessible. In addition to helping those with the disease, the effort aims to help companies planning trials to find participants for them. Antidote Technologies is a digital health company that aims to close the gap between medical research and the people who need it. Antidote Match, a clinical trial search tool, is one of the solutions. It will be available on MSAAās websiteĀ to allow visitors to find trials that are germane to them or their loved ones more easily, just by answering a few questions. The search engine uses natural language processing and artificial intelligence to help people find clinical trial matches. MS researchers are always testing potential treatments in clinical trials. Currently, there are over 100 trials in the United States alone that, combined, need over 115,000 people to participate. Eighty percent of trials can beĀ delayed, or closed, because of difficulties inĀ finding patients who want to take part. āAt MSAA, we recognize the importance of having resources and information available to help the MS community,” Gina Ross Murdoch, president and chief executive officer of MSAA, said in aĀ press release. “We also recognize the urgency involved in matching interested individuals with appropriate clinical trials to expedite MS research. We are proud to provide vital support services to individuals with MS, and we are thrilled to add the Antidote Match search tool to our offerings.ā As part of its mission to accelerate innovations that may benefit people withĀ MS, Antidote will provide its match tool at no cost to MSAA, as it does for other organizations the company works with. āSpeeding up research in MS will have a huge impact on the lives of patients and care partners,ā said Pablo Graiver, Antidoteās chief executive officer and founder. āWe look forward to the day when a cure has been discovered, and until then, weāre honored to work with MSAA to increase awareness of and access to MS clinical trials.ā Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags agreement, awareness, clinical trial, MSAA
April 24, 2024 News by Lindsey Shapiro, PhD Autoantibodies seen in blood years before MS diagnosis: Study
April 23, 2024 News by Mary Chapman Itās year 10 for MSAAās upcoming Improving Lives Benefit for MS
April 23, 2024 News by Margarida Maia, PhD AAN 2024: Subcutaneous Ocrevus led to nearly no relapses after year